SPDR S&P Biotech ETF
551 hedge funds and large institutions have $8.95B invested in SPDR S&P Biotech ETF in 2020 Q3 according to their latest regulatory filings, with 91 funds opening new positions, 190 increasing their positions, 155 reducing their positions, and 57 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
551
Holders Change
+29
Holders Change %
+5.56%
% of All Funds
11.15%
Holding in Top 10
11
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-35.29%
% of All Funds
0.22%
New
91
Increased
190
Reduced
155
Closed
57
Calls
$922M
Puts
$2.85B
Net Calls
-$1.92B
Net Calls Change
+$67.9M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$439M |
| 2 |
N
Natixis
Paris,
France
|
+$111M |
| 3 |
SG Americas Securities
New York
|
+$77.1M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$58.8M |
| 5 |
Squarepoint
New York
|
+$28.2M |
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$450M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$343M |
| 3 |
DFO
Duquesne Family Office
New York
|
-$123M |
| 4 |
Barclays
London,
United Kingdom
|
-$68M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$53.9M |
